Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

RADIENT RESTRUCTURED BY A PLANNED REVERSE MERGER

Every Time you you hit an updated Link you will get an update on every pertinent DD needed to get ready to Trade RXPC Public again...

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117058451

Re: Radient Restructured By A Planned Reverse Merger


From The Phoenix bizjournals published in 2014...WHY??? No need for the name Radient Pharmaceuticals to be mentioned on this board again you understand. We mentioned it here..lol

http://www.bizjournals.com/prnewswire/press_releases/2014/08/06/BR84813

http://www.bizjournals.com/prnewswire/press_releases/2014/08/06/BR84813

AMDL Inc. is NOW back to its main roots you understand..AMDL Inc. formerly known as Radient Pharmaceuticals..

Who will be their companion?

7.1.7 AMDL, Inc. (Radient Pharmaceuticals) 169

7.1.16 Biomarker Technologies, LLC 181

Which Web Site will they utilize?

http://provistacdx.com/

http://provistacdx.com/

What will be the USPTO protected Trade name of this companion company and which site will they utilize?

http://dtectdx.com/

http://dtectdx.com/



http://www.bizjournals.com/prnewswire/press_releases/2014/08/06/BR84813

WHO Is Biomarker Technologies LLC? They were a subsidiary of Provista Life Sciences that was sold to Provista Diagnostics Inc. according to William Gartner...

http://www.bizjournals.com/search?q=%22Biomarker+Technologies+LLC%22


Biomarker Technologies, LLC is an Arizona Domestic Llc filed on April 21, 2004. The company's File Number is listed as L11294708.

The Registered Agent on file for this company is William Gartner and is located at 2400 E Arizona Cir #1170, Phoenix, AZ 85016. The company's principal address is 2400 E Biltmore Cir #1170, Phoenix, AZ 85016.

The company has 2 principals on record. The principals are Warren Everett from Chattanooga TN and William Gartner from Phoenix AZ.


http://www.bizapedia.com/az/BIOMARKER-TECHNOLOGIES-LLC.html


Biomarker Technologies LLC develops diagnostic tests to detect breast cancer. The company offers BT Test, a blood diagnostic test that detects the presence of breast cancer at the molecular level. The company was founded in 2004 and is based in Phoenix, Arizona. Biomarker Technologies LLC operates as a subsidiary of Provista Life Sciences LLC.


Mr. William Gartner
Founder, Chief Executive Officer and President

Mr. Everett G. Warren
Founder and Chairman

http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=21816993


Provista Diagnostics, Inc. is a Nevada Domestic Corporation filed on November 12, 2009. The company's filing status is listed as Convert Out and its File Number is E0589842009-3.

The Registered Agent on file for this company is .secretary Of State and is located at 202 N. Carson St., Carson City, NV 89701-4201.

The company has 8 principals on record. The principals are David E Reese from Phoenix AZ, Everett Warren from Phoenix AZ, Jack Levine from Phoenix AZ, James R Zicarelli from Phoenix AZ, John Fermanis from Phoenix AZ, John Zicarelli from Phoenix AZ, Robert Hariri from Phoenix AZ, and William Gartner from Phoenix AZ.


http://www.bizapedia.com/nv/PROVISTA-DIAGNOSTICS-INC.html


$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

Companion Diagnostics in Personalized Medicine and Cancer Therapy

PR Newswire

LONDON, Aug. 6, 2014

7. Companies Entering the Companion Diagnostics Market 150

7.1.7 AMDL, Inc. (Radient Pharmaceuticals) 169

7.1.16 Biomarker Technologies, LLC 181


LONDON, Aug. 6, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Companion Diagnostics in Personalized Medicine and Cancer Therapy

http://www.reportbuyer.com/pharma_healthcare/diseases/cancer/companion_diagnostics_personalized_medicine_cancer_therapy.html


http://www.bizjournals.com/prnewswire/press_releases/2014/08/06/BR84813

Companion diagnostics (CDx) refers to a particular clinical diagnostic test that is under evaluation and is specifically linked to a known drug therapy. This linkage could be important in the therapeutic application and clinical outcome of a drug, such as with personalized medicine for oncology patients. The molecular diagnostics field plays a vital part in personalized medicine and has greatly expanded over the past twenty years, expanding by more than 20% annually compared to most other laboratory procedures. Research will continue to produce an increased understanding of disease processes, and diagnostics manufacturers will continue to expand and refine the technology and automation needed for clinical testing. Companion diagnostics, although smaller at present, is one of the fastest growing segments in the in vitro diagnostic (IVD) market.



http://www.bizjournals.com/prnewswire/press_releases/2014/08/06/BR84813



$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

7. Companies Entering the Companion Diagnostics Market 150
7.1 Industry Overview 150
7.1.1 20/20 GeneSystems, Inc. 152
7.1.2 Abbott Molecular, Inc. 153
7.1.3 Affymetrix, Inc. 156
7.1.4 Agendia BV 164
7.1.5 Agilent Technologies 166
7.1.6 Almac Group 167
7.1.7 AMDL, Inc. (Radient Pharmaceuticals) 169

7.1.8 Applied Biosystems 171
7.1.9 Asuragen, Inc. 172
7.1.10 Aureon Laboratories, Inc. 173
7.1.11 Beckman Coulter, Inc. (Danaher Corporation) 175
7.1.12 Becton, Dickinson and Company (BD) Diagnostics—TriPath 178
7.1.13 Biocode Hycel (Immunodiagnostics Systems [IDS]) 180
7.1.14 BioCurex, Inc. 180
7.1.15 Biodesix 181
7.1.16 Biomarker Technologies, LLC 181
7.1.17 Biomedical Diagnostics, LLC 182
7.1.18 Biomerica, Inc. 182
7.1.19 bioMérieux, Inc. 183
7.1.20 Biomira, Inc. (Oncothyreon, Inc.) 184
7.1.21 BioModa, Inc. 185
7.1.22 Bruker Daltonics 186
7.1.23 Byk Gulden 186
7.1.24 Cangen Biotechnologies, Inc. 186
7.1.25 Caprion Proteomics 188
7.1.26 Celera Diagnostics 190
7.1.27 Cepheid, Inc. 191
7.1.28 Clarient, Inc. (GE Healthcare) 193
7.1.29 Claros Diagnostics, Inc. 194
7.1.30 Clinical Data, Inc.: PGxHealth and Cogenics 194
7.1.31 Correlogic Systems, Inc. 197
7.1.32 CytoCore, Inc. (Formerly known as Molecular Diagnostics, Inc.) 197
7.1.33 Cytogen Corporation (now EUSA Pharma) 198

7.1.34 Dako (Agilent Technologies) 199
7.1.35 diaDexus 200
7.1.36 DiagnoCure 201
7.1.37 DRG International 203
7.1.38 EDP Biotech Corporation 204
7.1.39 Eisai Co., Ltd. 205
7.1.40 Eli Lilly & Co. 205
7.1.41 Epigenomics 206
7.1.42 Exact Sciences Corporation 207
7.1.43 Exagen Diagnostics, Inc. 208
7.1.44 Exigon 208
7.1.45 Gene Logic, Inc. 208
7.1.46 Genesis Genomics, Inc. (now known as Mitomics) 209
7.1.47 GenMark Diagnostics 210
7.1.48 Genomic Health, Inc. 211
7.1.49 Gen-Probe, Inc. (now known as Hologic Gen-Probe ) 212
7.1.50 Health Discovery Corporation 216
7.1.51 Ikonisys, Inc. 217
7.1.52 Illumina 218
7.1.53 Immunomedics 220
7.1.54 InterGenetics, Inc. 222
7.1.55 Ipsogen (QIAGEN Marseille) 222
7.1.56 Johnson & Johnson 224
7.1.57 LabCorp 225
7.1.58 Life Technologies Corporation (Thermo Fisher Scientific) 227
7.1.59 Matritech, Inc. 229
7.1.60 Miraculins 230

7.1.61 Mitsubishi Kagaku latron 231
7.1.62 Monogram Biosciences (Formerly ViroLogic, Inc. and now part of LabCorp) 231
7.1.63 Myriad Genetics, Inc. 232
7.1.64 NimbleGen Systems, Inc. 235
7.1.65 Northwest Biotherapeutics, Inc. 236
7.1.66 Novartis MDx 237
7.1.67 Nycomed (Takeda) 238
7.1.68 Oncotech, Inc. (Exiqon A/S) 239
7.1.69 Oncothyreon, Inc. (Formerly known as Biomira) 239
7.1.70 OPKO Health, Inc. 241
7.1.71 Orion Genomics 243
7.1.72 Oxford BioTherapeutics (Formerly Oxford Genome Sciences) 244
7.1.73 Panacea Pharmaceuticals, Inc. 245
7.1.74 Polymedco, Inc. 245
7.1.75 Power3 Medical Products 246
7.1.76 Prometheus Laboratories, Inc. (Nestlé Health Science S.A) 247
7.1.77 Proteome Systems Ltd. (Tyrian Diagnostics Ltd.) 247
7.1.78 Qiagen N.V. 248
7.1.79 Roche Molecular Diagnostics 252
7.1.80 Sanko Junyaku Co., Ltd. (Eisai Co., Ltd.) 254
7.1.81 SensiGen, LLC (Sequenom Center for Molecular Medicine) 255
7.1.82 Siemens Healthcare Diagnostics, Inc. 255
7.1.83 SuperArray Bioscience Corporation (Qiagen) 257
7.1.84 Third Wave Technologies, Inc. (now owned by Hologic Gen-Probe) 257
7.1.85 Tosoh Biosciences 259
7.1.86 Transgenomic, Inc. 259
7.1.87 TrimGen 259
7.1.88 Upstream Biosciences, Inc. (RealSource Residential, Inc.) 260
7.1.89 Ventana Medical Systems, Inc. 260
7.1.90 Veridex, LLC 262
7.1.91 Vermillion, Inc. (Formerly Ciphergen) 263
7.1.92 Vertex Pharmaceuticals, Inc. 263

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

Re: Radient Restructured By A Planned Reverse Merger
Back To The Future


Will needed to make the test better..DR-70 and ASU then stepped into the mix...


Biomarker touts new blood test for breast cancer
Nov 14, 2004,


Holding the worldwide rights to a diagnostic blood test for breast cancer, Biomarker Technologies LLC is helping a small laboratory in Virginia that developed the test but doesn't have the capital to take it to market.

Formed in February, Biomarker will usher the test through clinical studies and Food and Drug Administration approval. Those procedures will cost about $2 million, which is why the company is seeking angel investors.

Chief Executive William Gartner said the test could be commercially available by early 2005 if funding comes through.

In the meantime, he is relying on the same business model he used last year to market diagnostic products for GW Medical Technologies, another Phoenix company of which he also is CEO.

"Ultimately, our goal is to replace mammograms," Gartner said. "Being very conservative, we expect to replace 10 percent of mammograms done in the first year of availability. I'm really excited about getting this to the marketplace."

Biomarker's research shows that only about half the women who should get mammograms do so, in part because the test is uncomfortable. Moreover, mammograms miss at least 20 percent of cancers in women under the age of 40, contributing to the 40,000 deaths each year from breast cancer in the United States.

"The younger a woman is, the better the new blood test works, exceeding the benchmarks of 90 percent for specificity and sensitivity," Gartner said.

Before licensing a product, Biomarker assesses the clinical and patent status. Gartner is in discussions with four major diagnostic companies to use the test. Biomarker would receive royalties for its use.

Biomarker is seeking $3 million from investors, but Gartner said he hopes to get more than just money. Ideally, the investors would provide connections in the industry, such as with major pharmaceutical companies, he said.
Biomarker Technologies LLC

Oct 30, 2006,Phoenix Business Journal

Biomarker Technologies LLC, established by Gartner in 2004 …

Conference offers firms a financial boost
Gartner's RCP Diagnostics LLC received $1 million four months after he presented at the 2005 AAIC. The Phoenix translational in-vitro diagnostics company is completing clinical trials of a blood test for a variety of cancers in women, including cervical, uterine, ovarian and breast.The company is conducting blood tests for breast cancer, which are in the final clinical stage.

http://www.bizjournals.com/phoenix/stories/2006/10/30/story8.html

Jan 19, 2007,


Provista Life Sciences LLC announced Thursday that it has expanded its headquarters in the Biltmore area, allowing expansion of the three biotech companies operating under its umbrella.

The company said it will continue to lease space in its current suite, which will be converted to an on-site clinical diagnostics laboratory. Total square footage of the facilities now totals just under 5,000 square feet.

Provista Life Sciences is an umbrella organization that acquires the rights to medical diagnostics technologies and unifies operational and business development activities under a single management company.

The operation currently includes GW Medical Technologies LLC, focusing on a blood test to diagnose Alzheimer's disease; Biomarker Technologies LLC, focused on an early detection blood diagnostic for breast cancer; and RCP Diagnostics LLC, developing a screening diagnostic for women's estrogen-related cancers.Provista CEO William Gartner said "Relocating into larger headquarters allows Provista to more efficiently manage each operating unit's business resources. At the same time, we now have the ability to establish the clinical laboratory that will be pivotal to accelerating the commercialization of diagnostics technologies currently in the final testing stage."

http://www.bizjournals.com/phoenix/stories/2007/01/15/daily37.html



Patents take planning, patience
Sep 10, 2006,


"What we spend on patents alone would scare a lot of people," said William Gartner, president and chief executive of Phoenix-based Biomarker Technologies LLC. "Just to file the foreign applications on one of our patents, it costs us $44,000."

Then there's an annual fee that can range anywhere from $150 to $1,300, depending on the size of the country, he said.


Meanwhile, Gartner works with his patent attorney, Dan Noblitt, to get the blood test protected.

"All the big (law) firms in town have patent divisions," Gartner said. "The biggest problem you have is you almost need to find a patent attorney who has a specialization in your technology.
"Biomarker Technologies has a handful of patent applications for a blood test to detect breast cancer. The company is working with several local radiologists to recruit more than 700 women to participate in a trial that would take their blood when they get a mammogram or biopsy. The blood test looks at five biomarkers for breast cancer, in an attempt to catch changes in a woman's body before a lump would appear on a mammogram.



http://www.bizjournals.com/phoenix/stories/2006/09/11/focus6.html